The effect of L-arginine and creatine on vascular function and homocysteine metabolism

Vascular Medicine

Volumn 14, Issue 3, 2009, Pages 239-248

  Jahangir, Eiman ^a   Vita, Joseph A ^a   Handy, Diane ^b   Holbrook, Monica ^a   Palmisano, Joseph ^a   Beal, Ryan ^a   Loscalzo, Joseph ^b   Eberhardt, Robert T ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Creatine; Endothelial function; Homocysteine; L arginine; Methylation; Nitric oxide

Indexed keywords

ACETYLSALICYLIC ACID; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATINE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; GLYCERYL TRINITRATE; GUANIDINOACETIC ACID; HOMOCYSTEINE; METHIONINE; MULTIVITAMIN; NITRIC OXIDE; PLACEBO;

ADULT; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METHYLATION; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VITAMIN SUPPLEMENTATION;

AGED; ARGININE; BRACHIAL ARTERY; CORONARY ARTERY DISEASE; CREATINE; DIETARY SUPPLEMENTS; FEMALE; GLYCINE; HOMOCYSTEINE; HUMANS; HYPEREMIA; MALE; METHIONINE; MIDDLE AGED; REGIONAL BLOOD FLOW; TREATMENT OUTCOME; VASODILATION;

EID: 68449103558     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X08100834     Document Type: Article

References (52)

1. Michel T, Feron O. Nitric oxide synthases: Which, where, how, and why? J Clin Invest 1997; 100: 2146-2152.
2. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
3. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
4. Gokce N, Keaney JF, Menzoian JO, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function. Circulation 2002; 105: 1567-1572.
5. Girerd XJ, Hirsch AT, Cooke JP, Dzau VJ, Creager MA. l-Arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res 1990; 67: 1301-1308.
6. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. l-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248-1253.
7. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral l-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80: 331-333.
8. Lerman A, Burnett JCJ, Higano ST, McKinley LJ, Holmes DRJ. Long-term l-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97: 2123-2128.
9. Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanfield JE. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to l-arginine. J Am Coll Cardiol 1998; 32: 110-116.
10. Blum J, Hathaway L, Mincemoyer R, et al. Oral l-arginine in patients with coronary artery disease on medical management. Circulation 2000; 101: 2126-2129.
11. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. l-Arginine supplementation in peripheral arterial disease: No benefit and possible harm. Circulation 2007; 116: 188-195.
12. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang P. Effects of chronic treatment with l-arginine on atherosclerosis in ApoE knockout and ApoE/inducible NO synthase double-knockout mice. Arterioscler Thromb Vasc Biol 2003; 23: 97-103.
13. Schulman S, Becker L, Kass D, et al. l-Arginine therapy in acute myocardial infarction: VINTAGE MI (Vascular Interaction With Age in Myocardial Infarction Randomized Clinical) Trial. JAMA 2006; 295: 58-64.
14. 15N]citrulline labeling. Proc Natl Acad Sci USA 1996; 93: 11,460-11,465.
15. Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev 2001; 53: 161-176.
16. Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000; 80: 1107-1213.
17. Polotskaia A, Wang M, Patschan S, Addabbo F, Chen J, Goligorsky MS. Regulation of arginine methylation in endothelial cells: Role in premature senescence and apoptosis. Cell Cycle 2007; 20: 2524-2530.
18. Zhang JG, Liu ZH, Wang LZ, Jiang YD, Wang SR. Dysfunction of endothelial NO system originated from homocysteine-induced aberrant methylation pattern in promoter region of DDAH2 gene. Chin Med J 2007; 23: 2132-2137.
19. Jamaluddin MS, Yang X, Wang H. Hyperhomocysteinemia, DNA methylation and vascular disease. Clin Chem Lab Med 2007; 12: 1660-1666.
20. Loscalzo J. Adverse effects of supplemental l-arginine in atherosclerosis: Consequences of methylation stress in a complex catabolism. Arterioscler Thromb Vasc Biol 2002; 23: 3-5.
21. Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial function by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999; 281: 2113-2118.
22. Eberhardt RT, Forgione MA, Cap A, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106: 383-391.
23. McGuire DM, Gross MD, Van Pilsum JF, Towle HC. Repression of rat kidney l-arginine:gLycine amidinotransferase synthesis by creatine at a pretranslational level. J Biol Chem 1984; 259: 12,034-12,038.
24. Derave W, Marescau B, Eade E, Eijnde B, De Deyn P, Hespel P. Plasma guanidine compounds are altered by oral creatine supplementation in healthy humans. J Appl Physiol 2004; 97: 852-857.
25. Taes Y, Delannghe J, De Vriese A, Rombaut R, Camp J, Lameire N. Creatine supplementation decreases homocysteine in an animal model of uremia. Kidney Int 2003; 64: 1331-1337.
26. Stead LM, Au KP, Jacobs RL, Brosnan ME, Brosnan JT. Methylation demand and homocysteine metabolism: Effect of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab 2001; 281: E1095-E1100.
27. Korzun W. Oral creatine supplementation lowers plasma homocysteine concentrations in humans. Clin Lab Sci 2004; 17: 102-106.
28. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF, Vita JA. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93: 1107-1113.
29. Vita JA, Frei B, Holbrook M, Gokce N, Leaf C, Keaney Jr JF. l-2-oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J Clin Invest 1998; 101: 1408-1414.
30. Bodamer OA, Bloesch SM, Gregg AR, Stockler-Ipsiroglu S, O'Brien WE. Analysis of guanidinoacetate and creatine by isotope dilution electrospray tandem mass spectrometry. Clin Chim Acta 2001; 308: 173-178.
31. Newman DJ, Thakkar H, Edwads RG, et al. Serum cystatin c measured by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 1848-1876.
32. Larsson A, Malm J, Grubb A, Hansson L-O. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/ L. Scand J Clin Lab Invest 2004; 64: 25-30.
33. Widlansky ME, Gokce N, Keaney JF, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-1160.
34. Clarkson P, Adams M, Powe AJ, et al. Oral l-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97: 1989-1994.
35. Yi P, Melnyk S, Pogribna M, Pogribny IP, Hine RJ, James SJ. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J Biol Chem 2000; 275: 29,318-29,323.
36. West SG, Likos-Krick A, Brown P, Mariotti F. Oral l-arginine improves hemodynamic responses to stress and reduces plasma homocysteine in hypercholesterolemic men. J Nutr 2005; 135: 212-217.
37. Joseph J. Hyperhomocysteinemia and cardiovascular disease: New mechanisms beyond atherosclerosis. Metab Syndr Relat Disord 2003; 2: 97-104.
38. Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006; 354: 1629-1632.
39. Katusic Z. Mechanisms of endothelial dysfunction induced by aging: Role of arginase I. Circ Res 2007; 101: 640-641.
40. Boger RH. Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Ann Intern Med 2006; 38: 126-136.
41. Kielstein JT, Cooke JP. Should we measure asymmetric dimethylarginine in patients with coronary artery disease? Clin Chem 2007; 53: 161-163.
42. Zoccali CA, Kielstein JT. Asymmetric dimethylarginine: A new player in the pathogenesis of renal disease? Curr Opin Nephrol Hypertens 2006; 15: 314-320.
43. Steinberg E, Eknoyan G, Levin N, et al. Methods used to evaluate the quality of evidence underlying the National Kidney Foundation-Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: Description, findings, and implications. Am J Kidney Dis 2000; 36: 1-11.
44. Bennett-Richards KJ, Kattenhorn M, Donald AE, et al. Oral l-arginine does not improve endothelial dysfunction in children with chronic renal failure. Kidney Int 2002; 62: 1372-1378.
45. Miller HI, Dascalu A, Rassin TA, Wollman Y, Chernichowsky T, Iaina A. Effects of an acute dose of l-arginine during coronary angiography in patients with chronic renal failure. Am J Nephrol 2003; 23: 91-95.
46. Zhang XZ, Ardissino G, Ghio L, et al. l-Arginine supplementation in young renal allograft recipients with chronic renal dysfunction. Clin Nephrol 2001; 55: 453-459.
47. Terjung RL, Clarkson P, Eichner ER, et al. American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med Sci Sports Exerc 2000; 32: 706-717.
48. Steenge GR, Verhoef P, Greenhaff P. The effect of creatine and resistance training on plasma homocysteine concentration in healthy volunteers. Arch Intern Med 2001; 161: 1455-1456.
49. Taes Y, Delanghe J, DeBacquer D, et al. Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients. Kidney Int 2004; 66: 2422-2428.
50. Bostom AG, Bausseman L, Jacques PF, Liaugaudas G, Selhub J, Rosenberg IH. Cystatin C as a determinant of fasting plasma total homocysteine levels in coronary artery disease patients with normal serum creatinine. Arterioscler Thromb Vasc Biol 1999; 19: 2241-2244.
51. Ferreira LF, Hueber DM, Lutjemeier BJ, Townsend DK, Barstow TJ. Effects of creatine supplementation on body composition and renal function in rats. Med Sci Sports Exerc 2005; 37: 1525-1529.
52. Bostom AG, Gohh RY, Busserman L, et al. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. J Am Soc Nephrol 1999; 10: 164-166.